Palbociclib is a highly specific inhibitor of Cdk4 and Cdk6 with IC50s of 11 nM and16 nM.

Flavopiridol is a pan CDK inhibitor with IC50 values of 30nM, 40nM, 20-40nM, 60nM, 875nM and 20nM for CDK1, 2, 4, 6, 7, 9, respectively

AT7519 is a pan-CDKs inhibitor with IC50 values of 47, 13, <10nM for CDK2/CyclinA, CDK5/p35 and CDK9/CyclinT, and modest activity against CDK1/CyclinB, CDK3/CyclinE, CDK4/CyclinD1 and CDK6/CyclinD3 with IC50 values of 210, 360, 100 and 170nM, respectively.

JNJ-7706621 is a pan-CDK inhibitor that inhibits CDK1/2 with IC50 of 9/4 nM, also potently inhibits Aurora A/B.

Palbociclib isethionate is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases.

Abemaciclib is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM respectively, used for the treatment of advanced or metastatic breast cancers.

LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.

ON123300 is a potent and multi-targeted kinase inhibitor which inhibits CDK4, Ark5, PDGFRβ, FGFR1, RET, and Fyn with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM respectively.

P276-00 is a CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively.